Scholar Rock Wins FDA Approval for SMA Muscle Loss Drug

8:09 PM ETDeveloping

Health Desk

In Short: Scholar Rock's Isembyld, the first drug to target spinal muscle atrophy muscle loss, has received FDA approval, raising hopes for improved mobility in patients.

Scholar Rock has achieved a significant milestone with the FDA approval of Isembyld, the first drug designed to target muscle loss in spinal muscle atrophy (SMA), a rare neurological disorder. This approval marks a breakthrough for patients who may now have a better chance of improving their motor skills and independence.

However, the excitement around the new drug has also brought challenges, including the emergence of copycat versions of the experimental drug, which are being distributed before they have been fully tested. Experts warn that trial participants must meet strict criteria to receive the real drug or a placebo, highlighting the potential risks of unregulated use.

In a late-stage clinical trial, Isembyld showed promising results when combined with an SMN2-targeting drug, improving motor skills in young patients compared to those in the placebo group. The FDA's approval is a defining moment for the SMA community, as it represents a significant therapeutic breakthrough after decades of failed efforts in the industry.

Despite the approval, the high failure rate of drugs in Phase III trials, with only 50% eventually making it to the market, underscores the uncertainty surrounding the future of Isembyld. The drug's success will depend on its performance in larger, more diverse populations and its safety profile.

What's still developing

Tom accidentally took eight times the recommended dose of a fake version of retatrutide and says he nearly ended up in hospital Excitement around the creation of a new drug, especially one showing early promise in clinical trials, is often celebrated by those developing it.
But new weight-loss drug retatrutide has become a headache not only for Eli Lilly, the pharmaceutical company behind it, but for regulators in the UK and around the world.
Only 50% of drugs in this Phase III stage of testing in the US are eventually approved by the Food and Drug Administration (FDA), so there is no guarantee retatrutide will ever hit the market.
The high rate of failure is primarily down to drugs not working as well in large, diverse human populations as they do in smaller early tests, or because they reveal unexpected safety hazards.
Test your knowledge with our new weekday mini crossword Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter.
The FDA approved the drug, Isembyld, for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement.
“After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough.” To read the rest of this story subscribe to STAT+.
You may opt out of receiving STAT communications at any time.

Sources

STATlink